Every material Form 8-K Quantum-Si Inc has filed with the SEC since October 08, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Quantum-Si reported third-quarter 2026 revenue of $212,000, down from $552,000 a year earlier, as it transitions from its Platinum instrument to the Proteus platform. Net loss narrowed to $22.3 million from $35.7 million, and the company lowered its full-year 2026 guidance for adjusted operating expenses and total cash usage while keeping the Proteus launch target of the second quarter of 2027.
Q3 2026 revenue was $212,000 versus $552,000 in Q3 2025; nine-month revenue was $814,000 versus $2.0 million.
Q3 2026 net loss was $22.3 million versus $35.7 million a year earlier; the prior-year quarter included $13.6 million of net lease termination expense.
Full-year 2026 guidance for adjusted total operating expenses was lowered to $87.0 million or less from $98.0 million or less; total cash usage guidance was lowered to $87.0 million or less from $93.0 million.
Cash, cash equivalents and marketable securities were $149.4 million as of September 30, 2026; the company expects cash to fund operations into the fourth quarter of 2028.
Quantum-Si received notice from Nasdaq on October 14, 2026 that it regained compliance with the $1.00 minimum bid price requirement as of October 13, 2026, closing a matter that began with a July 23, 2026 deficiency notice. The company said it will keep monitoring its closing bid price, and it warned that if it fails to maintain compliance, Nasdaq will likely issue another delisting notice.
July 23, 2026: Nasdaq notice after the closing bid price stayed below $1.00 for 30 consecutive business days
October 13, 2026: Company regained compliance with the Bid Price Requirement, per Nasdaq's October 14 notice
Nasdaq determined the closing bid price was at or above $1.00 for at least 10 consecutive business days
October 15, 2026: Company issued a press release on the compliance, filed as Exhibit 99.1
Quantum-Si said it has demonstrated detection of 19 amino acids in its Proteus development program and is now working to deploy that capability into a developmental sequencing kit for R&D use. The company reaffirmed its target of demonstrating detection of all 20 amino acids by year-end 2026 and its planned commercial launch of Proteus in the second quarter of 2027, but the filing contains no financial results.
Detection of 19 amino acids demonstrated in the Proteus development program, announced October 8, 2026
Previously, a developmental kit detecting 18 amino acids was presented at the 2026 World HUPO Congress
Company target is detection of all 20 amino acids by year-end 2026
Proteus commercial launch is planned for the second quarter of 2027
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Quantum-Si Inc filing is on SEC EDGAR ↗. 8-K briefs of other companies →